Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
Abstract X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-10-01
|
| Series: | International Journal of Oral Science |
| Online Access: | https://doi.org/10.1038/s41368-023-00252-1 |
| _version_ | 1797577644797067264 |
|---|---|
| author | Kelsey A. Carpenter Delia O. Alkhatib Bryan A. Dulion Elizabeth Guirado Shreya Patel Yinghua Chen Anne George Ryan D. Ross |
| author_facet | Kelsey A. Carpenter Delia O. Alkhatib Bryan A. Dulion Elizabeth Guirado Shreya Patel Yinghua Chen Anne George Ryan D. Ross |
| author_sort | Kelsey A. Carpenter |
| collection | DOAJ |
| description | Abstract X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease, likely driven by poorly formed structures of the dentoalveolar complex, including the alveolar bone, cementum, dentin, and periodontal ligament. Our previous studies have demonstrated that sclerostin antibody (Scl-Ab) treatment improves phosphate homeostasis, and increases long bone mass, strength, and mineralization in the Hyp mouse model of XLH. In the current study, we investigated whether Scl-Ab impacts the dentoalveolar structures of Hyp mice. Male and female wild-type and Hyp littermates were injected with 25 mg·kg−1 of vehicle or Scl-Ab twice weekly beginning at 12 weeks of age and euthanized at 20 weeks of age. Scl-Ab increased alveolar bone mass in both male and female mice and alveolar tissue mineral density in the male mice. The positive effects of Scl-Ab were consistent with an increase in the fraction of active (nonphosphorylated) β-catenin, dentin matrix protein 1 (DMP1) and osteopontin stained alveolar osteocytes. Scl-Ab had no effect on the mass and mineralization of dentin, enamel, acellular or cellular cementum. There was a nonsignificant trend toward increased periodontal ligament (PDL) attachment fraction within the Hyp mice. Additional PDL fiber structural parameters were not affected by Scl-Ab. The current study demonstrates that Scl-Ab can improve alveolar bone in adult Hyp mice. |
| first_indexed | 2024-03-10T22:12:02Z |
| format | Article |
| id | doaj.art-14d45fb9072542ce8da296b6dbf58154 |
| institution | Directory Open Access Journal |
| issn | 2049-3169 |
| language | English |
| last_indexed | 2024-03-10T22:12:02Z |
| publishDate | 2023-10-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | International Journal of Oral Science |
| spelling | doaj.art-14d45fb9072542ce8da296b6dbf581542023-11-19T12:34:09ZengNature Publishing GroupInternational Journal of Oral Science2049-31692023-10-0115111010.1038/s41368-023-00252-1Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)Kelsey A. Carpenter0Delia O. Alkhatib1Bryan A. Dulion2Elizabeth Guirado3Shreya Patel4Yinghua Chen5Anne George6Ryan D. Ross7Department of Anatomy & Cell Biology, Rush University Medical CenterDepartment of Anatomy & Cell Biology, Rush University Medical CenterDepartment of Anatomy & Cell Biology, Rush University Medical CenterDepartment of Oral Biology, The University of Illinois at ChicagoDepartment of Anatomy & Cell Biology, Rush University Medical CenterDepartment of Oral Biology, The University of Illinois at ChicagoDepartment of Oral Biology, The University of Illinois at ChicagoDepartment of Anatomy & Cell Biology, Rush University Medical CenterAbstract X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease, likely driven by poorly formed structures of the dentoalveolar complex, including the alveolar bone, cementum, dentin, and periodontal ligament. Our previous studies have demonstrated that sclerostin antibody (Scl-Ab) treatment improves phosphate homeostasis, and increases long bone mass, strength, and mineralization in the Hyp mouse model of XLH. In the current study, we investigated whether Scl-Ab impacts the dentoalveolar structures of Hyp mice. Male and female wild-type and Hyp littermates were injected with 25 mg·kg−1 of vehicle or Scl-Ab twice weekly beginning at 12 weeks of age and euthanized at 20 weeks of age. Scl-Ab increased alveolar bone mass in both male and female mice and alveolar tissue mineral density in the male mice. The positive effects of Scl-Ab were consistent with an increase in the fraction of active (nonphosphorylated) β-catenin, dentin matrix protein 1 (DMP1) and osteopontin stained alveolar osteocytes. Scl-Ab had no effect on the mass and mineralization of dentin, enamel, acellular or cellular cementum. There was a nonsignificant trend toward increased periodontal ligament (PDL) attachment fraction within the Hyp mice. Additional PDL fiber structural parameters were not affected by Scl-Ab. The current study demonstrates that Scl-Ab can improve alveolar bone in adult Hyp mice.https://doi.org/10.1038/s41368-023-00252-1 |
| spellingShingle | Kelsey A. Carpenter Delia O. Alkhatib Bryan A. Dulion Elizabeth Guirado Shreya Patel Yinghua Chen Anne George Ryan D. Ross Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) International Journal of Oral Science |
| title | Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) |
| title_full | Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) |
| title_fullStr | Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) |
| title_full_unstemmed | Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) |
| title_short | Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH) |
| title_sort | sclerostin antibody improves alveolar bone quality in the hyp mouse model of x linked hypophosphatemia xlh |
| url | https://doi.org/10.1038/s41368-023-00252-1 |
| work_keys_str_mv | AT kelseyacarpenter sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT deliaoalkhatib sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT bryanadulion sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT elizabethguirado sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT shreyapatel sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT yinghuachen sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT annegeorge sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh AT ryandross sclerostinantibodyimprovesalveolarbonequalityinthehypmousemodelofxlinkedhypophosphatemiaxlh |